Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


28.01.2019

1 Adv Anat Pathol
1 Arch Pathol Lab Med
2 BJU Int
2 Cancer Causes Control
1 Cancer Manag Res
1 Eur J Cancer
2 Eur Radiol
1 Eur Rev Med Pharmacol Sci
1 Eur Urol
1 Genet Mol Biol
1 Health Qual Life Outcomes
1 Int J Cancer
1 Int J Urol
1 J Cancer
1 J Cell Biochem
1 J Steroid Biochem Mol Biol
1 J Transl Med
4 J Urol
1 Metabolites
1 Minerva Urol Nefrol
1 Mol Ther
1 Nucleosides Nucleotides Nucleic Acids
1 Onco Targets Ther
1 Oncogene
4 Oncol Lett
1 Phytomedicine
1 PLoS One
1 Sci Rep
1 Tumori
3 Urol Oncol
2 Urology
1 Vet Microbiol
2 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Adv Anat Pathol

  1. COX RM, Magi-Galluzzi C, McKenney JK
    Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
    Adv Anat Pathol. 2018;25:387-399.
    PubMed     Text format     Abstract available


    Arch Pathol Lab Med

  2. GUO CC, Czerniak B
    Bladder Cancer in the Genomic Era.
    Arch Pathol Lab Med. 2019 Jan 23. doi: 10.5858/arpa.2018-0329.
    PubMed     Text format     Abstract available


    BJU Int

  3. BAJIC P, Wolfe AJ, Gupta GN
    Old Instillations and New Implications in Bladder Cancer: The Urinary Microbiome and Intravesical BCG.
    BJU Int. 2019 Jan 21. doi: 10.1111/bju.14683.
    PubMed     Text format     Abstract available

  4. D'ANDREA D, Soria F, Zehetmayer S, Gust KM, et al
    Diagnostic accuracy, clinical utility and influence on decision making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14673.
    PubMed     Text format     Abstract available


    Cancer Causes Control

  5. KWAN ML, Kushi LH, Danforth KN, Roh JM, et al
    The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer.
    Cancer Causes Control. 2019 Jan 17. pii: 10.1007/s10552-019-1130.
    PubMed     Text format     Abstract available

  6. AMR S, Wolpert BJ, St George DM, James I, et al
    Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause.
    Cancer Causes Control. 2019 Jan 21. pii: 10.1007/s10552-019-1131.
    PubMed     Text format     Abstract available


    Cancer Manag Res

  7. ZHAO S, Xie Q, Yang R, Wang J, et al
    High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.
    Cancer Manag Res. 2019;11:587-598.
    PubMed     Text format     Abstract available


    Eur J Cancer

  8. ROUANNE M, Betari R, Radulescu C, Goubar A, et al
    Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.
    Eur J Cancer. 2019;108:111-119.
    PubMed     Text format     Abstract available


    Eur Radiol

  9. GIRARD A, Rouanne M, Taconet S, Radulescu C, et al
    Integrated analysis of (18)F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer.
    Eur Radiol. 2019 Jan 21. pii: 10.1007/s00330-018-5959.
    PubMed     Text format     Abstract available

  10. WANG F, Chen HG, Zhang RY, Jin D, et al
    Diffusion kurtosis imaging to assess correlations with clinicopathologic factors for bladder cancer: a comparison between the multi-b value method and the tensor method.
    Eur Radiol. 2019 Jan 21. pii: 10.1007/s00330-018-5977.
    PubMed     Text format     Abstract available


    Eur Rev Med Pharmacol Sci

  11. FU YR, Chen F, Luo Y, Yi YF, et al
    Nanoscale bubble ultrasound contrast agents-mediated suicide gene therapy system, Nanoscale bubble-LV5-YCD-TK/GCV/5-FC, effectively inhibits bladder cancer cell growth.
    Eur Rev Med Pharmacol Sci. 2019;23:75-86.
    PubMed     Text format     Abstract available


    Eur Urol

  12. ZUIVERLOON TCM, Theodorescu D
    Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2019 Jan 17. pii: S0302-2838(18)31024.
    PubMed     Text format    


    Genet Mol Biol

  13. RAJA SA, Abbas S, Shah STA, Tariq A, et al
    Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer.
    Genet Mol Biol. 2019 Jan 21:0. doi: 10.1590/1678-4685-GMB-2017-0339.
    PubMed     Text format     Abstract available


    Health Qual Life Outcomes

  14. TAARNHOJ GA, Johansen C, Pappot H
    Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature.
    Health Qual Life Outcomes. 2019;17:20.
    PubMed     Text format     Abstract available


    Int J Cancer

  15. TURNER MC, Gracia-Lavedan E, Cirac M, Castano-Vinyals G, et al
    Ambient air pollution and incident bladder cancer risk: updated analysis of the Spanish Bladder Cancer Study.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32136.
    PubMed     Text format     Abstract available


    Int J Urol

  16. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment from Dr Miyata et al. to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2019 Jan 22. doi: 10.1111/iju.13893.
    PubMed     Text format     Abstract available


    J Cancer

  17. JIN S, Wang B, Zhu Y, Dai W, et al
    Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with pN and Lymph Node Ratio.
    J Cancer. 2019;10:249-256.
    PubMed     Text format     Abstract available


    J Cell Biochem

  18. QIU F, Zhang MR, Zhou Z, Pu JX, et al
    lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation, metastasis and epithelial-mesenchymal transition in bladder cancer.
    J Cell Biochem. 2019 Jan 22. doi: 10.1002/jcb.28373.
    PubMed     Text format     Abstract available


    J Steroid Biochem Mol Biol

  19. DUNN JA, Jefferson K, MacDonald D, Iqbal G, et al
    LOW SERUM 25-HYDROXYVITAMIN D IS ASSOCIATED WITH INCREASED BLADDER CANCER RISK: A SYSTEMATIC REVIEW AND EVIDENCE OF A POTENTIAL MECHANISM.
    J Steroid Biochem Mol Biol. 2019 Jan 14. pii: S0960-0760(18)30620.
    PubMed     Text format     Abstract available


    J Transl Med

  20. FURUYA H, Chan OTM, Pagano I, Zhu C, et al
    Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.
    J Transl Med. 2019;17:29.
    PubMed     Text format     Abstract available


    J Urol

  21. CHANG SS
    Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553308.83315.
    PubMed     Text format    

  22. EBRAHIMI H, Amini E, Pishgar F, Moghaddam SS, et al
    Global, Regional, and National Burden of Bladder Cancer, 1990 - 2016: Results from the Global Burden of Disease Study 2016.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000025.
    PubMed     Text format     Abstract available

  23. CHANG SS
    Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000097.
    PubMed     Text format    

  24. ATALA A
    Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553307.75692.
    PubMed     Text format    


    Metabolites

  25. RODRIGUES D, Pinto J, Araujo AM, Jeronimo C, et al
    GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells.
    Metabolites. 2019;9.
    PubMed     Text format     Abstract available


    Minerva Urol Nefrol

  26. MISTRETTA FA, Carrion DM, Nazzani S, Vasquez JL, et al
    Bladder recurrence of primary upper tract urinary carcinoma following nephro-ureterectomy, and risk of upper urinary tract recurrence after ureteral stent positioning in patients with primary bladder cancer: a contemporary non-systematic review of the
    Minerva Urol Nefrol. 2019 Jan 17. pii: S0393-2249.19.03311.
    PubMed     Text format     Abstract available


    Mol Ther

  27. CHEN Z, Chen X, Xie R, Huang M, et al
    DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.
    Mol Ther. 2019 Jan 9. pii: S1525-0016(19)30004.
    PubMed     Text format     Abstract available


    Nucleosides Nucleotides Nucleic Acids

  28. MIERZEJEWSKA P, Gawlik-Jakubczak T, Jablonska P, Czajkowski M, et al
    Nicotinamide metabolism alterations in bladder cancer: Preliminary studies.
    Nucleosides Nucleotides Nucleic Acids. 2019.
    PubMed     Text format     Abstract available


    Onco Targets Ther

  29. WU J, Li W, Ning J, Yu W, et al
    Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition.
    Onco Targets Ther. 2019;12:495-508.
    PubMed     Text format     Abstract available


    Oncogene

  30. CHENG M, Sheng L, Gao Q, Xiong Q, et al
    The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network.
    Oncogene. 2019 Jan 18. pii: 10.1038/s41388-019-0683.
    PubMed     Text format     Abstract available


    Oncol Lett

  31. XU Z, Zhang Q, Luh F, Jin B, et al
    Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer.
    Oncol Lett. 2019;17:1865-1876.
    PubMed     Text format     Abstract available

  32. HOU Y
    MiR-506 inhibits cell proliferation, invasion, migration and epithelial-to-mesenchymal transition through targeting RWDD4 in human bladder cancer.
    Oncol Lett. 2019;17:73-78.
    PubMed     Text format     Abstract available

  33. YE G, Kan S, Chen J, Lu X, et al
    Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway.
    Oncol Lett. 2019;17:195-200.
    PubMed     Text format     Abstract available

  34. WANG X, Wang H, Song Y
    Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
    Oncol Lett. 2019;17:201-208.
    PubMed     Text format     Abstract available


    Phytomedicine

  35. DAGA M, Pizzimenti S, Dianzani C, Cucci MA, et al
    Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Phytomedicine. 2018;56:156-164.
    PubMed     Text format     Abstract available


    PLoS One

  36. BYUN SJ, Park W, Cho KH, Cho J, et al
    A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16).
    PLoS One. 2019;14:e0209998.
    PubMed     Text format     Abstract available


    Sci Rep

  37. YEE CH, Zheng Z, Shuman L, Yamashita H, et al
    Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
    Sci Rep. 2019;9:270.
    PubMed     Text format     Abstract available


    Tumori

  38. LU JJ, Su YW, Wang CJ, Li DF, et al
    Semaphorin 4D promotes the proliferation and metastasis of bladder cancer by activating the PI3K/AKT pathway.
    Tumori. 2019 Jan 24:300891618811280. doi: 10.1177/0300891618811280.
    PubMed     Text format     Abstract available


    Urol Oncol

  39. YAP SA, Brunson A, Pugashetti N, M P H RDC, et al
    Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence.
    Urol Oncol. 2018;36:498.
    PubMed     Text format     Abstract available

  40. EISSA S, Safwat M, Matboli M, Zaghloul A, et al
    Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer.
    Urol Oncol. 2019 Jan 14. pii: S1078-1439(18)30518.
    PubMed     Text format     Abstract available

  41. KRASNOW RE, Rodriguez D, Nagle RT, Mossanen M, et al
    The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Urol Oncol. 2018;36:500.
    PubMed     Text format     Abstract available


    Urology

  42. GONZALEZ AN, Lipsky MJ, Li G, Rutman MP, et al
    The prevalence of bladder cancer during cystoscopy for asymptomatic microscopic hematuria.
    Urology. 2019 Jan 21. pii: S0090-4295(19)30073.
    PubMed     Text format     Abstract available

  43. LOH-DOYLE JC, Ashrafi A, Nazemi A, Ghodoussipour S, et al
    Dual Prosthetic Implantation After Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    Urology. 2019 Jan 18. pii: S0090-4295(19)30065.
    PubMed     Text format     Abstract available


    Vet Microbiol

  44. RUSSO V, Roperto F, Taulescu M, De Falco F, et al
    Expression of the feline leukemia virus subgroup C receptors in normal and neoplastic urothelium of the urinary bladder of cattle associated with bovine papillomavirus infection.
    Vet Microbiol. 2019;229:147-152.
    PubMed     Text format     Abstract available


    World J Urol

  45. GUPTA M, Milbar N, Tema G, Pederzoli F, et al
    Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
    World J Urol. 2019 Jan 23. pii: 10.1007/s00345-018-02624.
    PubMed     Text format     Abstract available

  46. BLACK P, Gontero P
    SIU-ICUD consultation on bladder cancer 2018.
    World J Urol. 2019 Jan 21. pii: 10.1007/s00345-018-2601.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: